Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Treasury Shares: 2014-2024

Historic Treasury Shares for Viridian Therapeutics, Inc.\DE (VRDN) over the last 4 years, with Dec 2024 value amounting to $314,075.

  • Viridian Therapeutics, Inc.\DE's Treasury Shares rose 111.93% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 111.93%. This contributed to the annual value of $314,075 for FY2024, which is 60.98% down from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Treasury Shares stood at $314,075 for FY2024, which was down 60.98% from $804,947 recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Treasury Shares ranged from a high of $804,947 in FY2023 and a low of $314,075 during FY2024.
  • For the 2-year period, Viridian Therapeutics, Inc.\DE's Treasury Shares averaged around $559,511, with its median value being $559,511 (2023).
  • Data for Viridian Therapeutics, Inc.\DE's Treasury Shares shows a maximum YoY plummeted of 60.98% (in 2024) over the last 5 years.
  • Over the past 2 years, Viridian Therapeutics, Inc.\DE's Treasury Shares (Yearly) stood at $804,947 in 2023, then slumped by 60.98% to $314,075 in 2024.